4/A: Edwards Lifesciences CEO Amends Form 4 Filing to Correctly Report 401(k) Holdings

Bernard J. Zovighian, CEO of Edwards Lifesciences, amended a previous Form 4 filing to accurately reflect indirect beneficial ownership of common stock held within the company's 401(k) plan.

Summary

• Bernard J. Zovighian, CEO of Edwards Lifesciences, filed an amended Form 4 with the SEC on June 13, 2024.
• This amendment corrects a previous filing from May 7, 2024, regarding changes in beneficial ownership.
• The amendment removes the reporting of an acquisition of 580.2601 shares on May 6, 2024, as it was an exempt transaction under Rule 16b-3.
• The filing now accurately discloses the number of shares beneficially owned indirectly through the Issuer's 401(k) Plan, totaling 3,267.6552 shares.
• The shares were acquired under the Issuer's 401(k) Plan in a transaction exempted by Rule 16b-3, as well as 2,558 shares held under the Issuer's 401(k) Plan that were previously reported as directly held.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't indicate any significant positive or negative developments for the company, but accuracy in reporting is always viewed favorably.

Industry Context

Form 4 filings are a routine part of insider trading regulations, ensuring transparency in the market regarding the buying and selling of company stock by its executives and directors. This specific filing relates to correcting the reporting of shares held within a 401(k) plan, which is a common occurrence.

Stakeholder Impact

• The correction of the Form 4 filing ensures accurate information is available to shareholders regarding insider ownership.

Key Dates